Fig. 7

HiPSC-derived cells treated with IL10 exhibit an increased ability to promote blood flow perfusion recovery and enhance vasculogenesis and angiogenesis after hindlimb ischemia (HLI). Mice underwent with HLI procedure were randomly injected with 30 μl medium control (medium ctrl, n=6 mice), or 30 μl medium containing one million of hiPSC-derived cells treated with control (hiPSC-cells (ctrl), n=5 mice) or IL10 (hiPSC-cells (IL10), n=6 mice), respectively. Immunosuppression was established prior to the procedure and maintained via orogastric cyclosporin at a dose of 5 mg/kg until the end of protocol. Laser doppler perfusion images (LDPI) acquisitions were conducted at day 1, 7 and 14 post-ischemia. Representative LDPIs in supine position (A) and quantitative data of LDPI perfusion of ischemic legs were presented here. (C-E) IF analysis of gastrocnemius muscle. Gastrocnemius muscles were harvested at day 21 post-HLI and subjected to IF analysis with human specific CD31 antibody (red) and lycopersicon esculentum agglutinin (LEA) lectin (green). LEA-positive area was quantified using Image J. CD31+/LEA+ cells and total LEA+ cells were manually counted from each image Three images from each animal were quantified and averaged. Representative images (C) and quantitative data of LEA-positive area (D) or percentages of CD31+/LEA+ cells (E) were presented here, respectively. *P<0.05 (vs medium ctrl), #P<0.05 (vs hiPSC-EC (ctrl)).